Full-Time

Director – Process Chemistry

Confirmed live in the last 24 hours

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

No salary listed

Senior, Expert

Cambridge, MA, USA

Hybrid position; in-office days required.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Master's degree or PhD in organic chemistry with 12+ years of relevant process chemistry and drug development experience in the Pharmaceutical industry
  • 5+ years of supervisory/management experience
Responsibilities
  • Demonstrates advanced intellectual and technical leadership
  • Leads peers scientifically with consistently excellent experimental design and productive innovation with a record of successful initiatives and excellent understanding of related scientific disciplines
  • Assesses data integrity to provide expert interpretation and recommendations to project teams
  • Effectively manages CDMOs/CROs, their contracts and other external collaborations
  • Generate ideas and champion initiatives to extend, enhance and diversify Process Chemistry's capabilities and the wider organization
  • Presents clearly and persuasively to all parts of the Blueprint organization and to our collaborators
  • Coordinates and authors publications, patents, and regulatory submissions as well as external communications
  • Provides strategic direction and scientific leadership for multidisciplinary CMC project teams, manage timelines, milestones, budgets, and objectives
  • Assists in the development and communication of department goals and strategy
  • As a people manager within the organization, supervises, mentors, and guides the career development of staff
  • Performs other responsibilities as assigned
Desired Qualifications
  • Ability to adapt to working optimally within a variety of situations; adapts to change and to changes in job demands
  • Demonstrated and proven expertise and experience with process development and scale-up
  • Expert knowledge of regulatory requirements in the pharmaceutical industry
  • Ability to optimally express ideas in written and oral context; collaboration, team-building skills, and interpersonal skills; genuine desire to be on a team and contribute to organizational and team goals. Ability to lead with a passion and optimism to participate in a fast-paced environment characterized by rigorous science and innovative thinking
  • Ability to build productive working relationships across a multi-disciplinary internal team and effectively manage CRO/CDMO and other external collaborations
  • Demonstration of effective organizational and time management skills and execution
  • Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for targeted therapies boosts Blueprint Medicines' market potential.
  • FDA initiatives expedite approval for Blueprint's innovative systemic mastocytosis treatments.
  • Increasing systemic mastocytosis prevalence aligns with Blueprint's therapeutic focus.

What critics are saying

  • Competition from Deciphera Pharmaceuticals' KIT inhibitor, ripretinib, poses a market threat.
  • Stringent European regulations may hinder Blueprint's market expansion.
  • Potential patent expirations could lead to generic competition and revenue loss.

What makes Blueprint Medicines unique

  • Blueprint Medicines leads in mast cell-targeted therapies with AYVAKIT and BLU-808.
  • AYVAKIT shows long-term efficacy and safety in treating indolent systemic mastocytosis.
  • BLU-808 offers a wide therapeutic window as a first-in-class oral KIT inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
ETF Daily News
Mar 8th, 2025
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Proficio Capital Partners LLC makes new $1.01 million investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Defense World
Mar 7th, 2025
Truist Financial Corp Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Truist Financial Corp makes new investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Medical Update Online
Mar 4th, 2025
Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025

Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025.

PR Newswire
Feb 28th, 2025
Blueprint Medicines Highlights Leading Portfolio Of Mast Cell-Targeted Therapies At 2025 Aaaai / Wao Joint Congress

-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy ---- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course ---- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor --CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting the urgency to treat. In addition, the company will report positive data from the Phase 1 healthy volunteer trial evaluating BLU-808, an investigational, highly potent and selective oral inhibitor of wild-type KIT, consistent with top-line data previously announced in January 2025. A total of 14 data presentations, including two oral presentations, will be reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress being held February 28-March 3 in San Diego."We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations highlighting more than a decade of leadership and collaboration with the mast cell disease community, including renowned medical institutions pioneering innovative research and multi-disciplinary patient care," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "In ISM, new data have reinforced that AYVAKIT was very well-tolerated after multiple years of treatment, with a low discontinuation rate and safety results that have remained consistent with the safety profile from the placebo-controlled study as summarized in the FDA-approval label

Defense World
Feb 17th, 2025
Blueprint Medicines Corporation Reports Strong Financial Results for 2024

Furthermore, Blueprint Medicines announced the appointment of Sherwin Sattarzadeh as Chief Business Officer, succeeding Helen Ho.